|Drug class||Orexin receptor agonist|
|Chemical and physical data|
|Molar mass||424.56 g·mol−1|
|3D model (JSmol)|
Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist. It is a small-molecule compound and is administered intravenously. The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. It is related to another orexin receptor agonist known as TAK-994, the development of which was discontinued for safety reasons in October 2021.